A single-arm, phase II study of niraparib and bevacizumab maintenance therapy in platinum-sensitive, recurrent ovarian cancer patients previously treated with a PARP inhibitor: Korean Gynecologic Oncology Group (KGOG 3056)/NIRVANA-R trial

BACKGROUND: Given the expanding clinical use of poly(adenosine diphosphate [ADP]-ribose) polymerase inhibitors (PARPis), there is a significant need for optimal strategies with which to treat patients whose cancer progresses while using a PARPi. However, the treatment consensus after PARPi has not b...

Descripción completa

Detalles Bibliográficos
Autores principales: Park, Junsik, Lim, Myong Cheol, Lee, Jae-Kwan, Jeong, Dae Hoon, Kim, Se Ik, Choi, Min Chul, Kim, Byoung-Gie, Lee, Jung-Yun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Asian Society of Gynecologic Oncology; Korean Society of Gynecologic Oncology; Japan Society of Gynecologic Oncology 2021
Materias:
Clinical Trial Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8899880/
https://www.ncbi.nlm.nih.gov/pubmed/34910393
http://dx.doi.org/10.3802/jgo.2022.33.e12

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8899880/
https://www.ncbi.nlm.nih.gov/pubmed/34910393
http://dx.doi.org/10.3802/jgo.2022.33.e12

Ejemplares similares